H. Kent Holland, M.D., is board certified in the subspecialties of oncology and hematology. He is Medical Director of the Blood and Marrow Transplant Program at Northside Hospital, Co-Director of the Northside Hospital Stem Cell Processing Laboratory and Medical Director of the Atlanta Blood Services Apheresis Collection Facility. Dr. Holland is also a Northside Hospital Leukemia Program physician. From 2013 – 2022, Dr. Holland was recognized as among Atlanta’s Top Doctors in his specialty by Castle Connolly.
- B.S.E., Duke University
- M.D., Alpha Omega Alpha Honor Society, Southwestern Medical School in Dallas, Texas
- Residency, Cornell University Medical Center and Sloan Kettering Cancer Center
- Fellowship in Hematology-Oncology/Bone Marrow Transplantation, Johns Hopkins School of Medicine
Foundation for the Accreditation of Cellular Therapy (FACT)
- FACT Inspector- national organization that inspects and accredits bone marrow transplant programs nationally
- FACT Accreditation Committee (2007-2008)
American Society of Blood and Marrow Transplant
- ASBMT Board of Directors (2006-2009)
- American Society of Hematology
- American Society of Clinical Oncology
- American Society for Blood & Marrow Transplant
- International Society for Experimental Hematology
- American Association of Blood Banks
- Castle Connolly. American Top Doctors (2001-2006)
- America’s Top Physicians, Consumers’ Research Council of America (2003-2009)
Past Academic Faculty Appointments
- Johns Hopkins Faculty member, Bone Marrow Transplant Program
- Assistant Director of the Johns Hopkins’ Hemapheresis Center.
- Emory University-Associate Professor of Medicine, Bone Marrow Transplant Program
- Director of Emory University’s Hemapheresis Center and Stem Cell Laboratory
- Authored and co-authored over 190 research articles and abstracts in peer-reviewed journals; Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, Biology of Blood and Marrow Transplantation
Dr. Holland’s clinical and research interests include novel approaches to allogeneic blood and marrow transplantation and leukemia therapies.